Search clinical trials for: bidridistrogene xeboparvovec

Total 2 results

Sarepta Therapeutics, Inc.

Recruiting

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)

Limb-girdle Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Active, not recruiting

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Limb-Girdle Muscular Dystrophy, Type 2E

United States

3

Subscribe